Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program

References

• Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383–93.
   PubMed Web of Science ®Google Scholar
• June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007;117:1204–12.
   PubMed Web of Science ®Google Scholar
• June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466–76.
   PubMed Web of Science ®Google Scholar
• Levine BL. T lymphocyte engineering ex vivo for cancer and infectious disease. Expert Opin Biol Ther 2008;8:475–89.
   PubMed Web of Science ®Google Scholar
• Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, . Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003;102:2004–13.
   PubMed Web of Science ®Google Scholar
• Levine BL, Cotte J, Small CC, Carroll RG, Riley JL, Bernstein WB, . Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998;7:437–48.
   PubMedGoogle Scholar
• Rapoport AP, Levine BL, Badros A, Meisenberg B, Ruehle K, Nandi A, . Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant 2004;33:53–60.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, . Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005;11:1230–7.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, . A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006;107:1325–31.
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr, de Vries CR, Allen T, Ahmadzadeh M, Rosenberg SA. Inability to mediate prolonged reduction of regulatory T cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J Immunother 2007;30:438–47.
   PubMed Web of Science ®Google Scholar
• Thistlethwaite FC, Elkord E, Griffiths RW, Burt DJ, Shablak AM, Campbell JD, . Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother 2008;57:623–34.
   PubMed Web of Science ®Google Scholar
• Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, . Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698–703.
   PubMed Web of Science ®Google Scholar
• Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006;24:5060–9.
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 2006;177:6527–39.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, . Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126–9.
   PubMed Web of Science ®Google Scholar
• Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, . Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103:17372–7.
   PubMed Web of Science ®Google Scholar
• Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, . Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000;96:467–74.
   PubMed Web of Science ®Google Scholar
• Ino K, Ageitos AG, Singh RK, Talmadge JE. Activation-induced T cell apoptosis by monocytes from stem cell products. Int Immunopharmacol 2001;1:1307–19.
   Google Scholar
• Bryn T, Yaqub S, Mahic M, Henjum K, Aandahl EM, Tasken K. LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. Int Immunol 2008;20:235–45.
   PubMed Web of Science ®Google Scholar
• Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E, Schuler G. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J Immunol Methods 2005;298:61–72.
   PubMed Web of Science ®Google Scholar
• Elias M, van Zanten ZJ, Hospers GA, Setroikromo A, de Jong MA, de Leij LF, Mulder NH. Closed system generation of dendritic cells from a single blood volume for clinical application in immunotherapy. J Clin Apher 2005;20:197–207.
   Google Scholar
• Erdmann M, Dorrie J, Schaft N, Strasser E, Hendelmeier M, Kampgen E, . Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother 2007;30:663–74.
   PubMed Web of Science ®Google Scholar
• Gulen D, Abe F, Maas S, Reed E, Cowan K, Pirruccello S, Wisecarver J, . Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors. Int Immunopharmacol 2008;8:1728–36.
   PubMed Web of Science ®Google Scholar
• Jarnjak-Jankovic S, Hammerstad H, Saeboe-Larssen S, Kvalheim G, Gaudernack G. A full scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines. BMC Cancer 2007;7:119.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim HO, Baek EJ, Choi Y, Kim HS, Lee MG. Monocyte enrichment from leukapheresis products by using the Elutra cell separator. Transfusion 2007;47:2290–6.
   PubMedGoogle Scholar
• Lemarie C, Sugaye R, Kaur I, Taga T, Chabannon C, Schuyler R, McMannis J. Purification of monocytes from cryopreserved mobilized apheresis products by elutriation with the Elutra device. J Immunol Methods 2007;318:30–6.
   PubMedGoogle Scholar
• Perseghin P, D'Amico G, Dander E, Gaipa G, Dassi M, Biagi E, Biondi A. Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation device. Transfusion 2008;48:1644–9.
   PubMedGoogle Scholar
• Pullarkat V, Lau R, Lee SM, Bender JG, Weber JS. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods 2002;267:173–83.
   PubMed Web of Science ®Google Scholar
• Rouard H, Leon A, De Reys S, Taylor L, Logan J, Marquet J, . A closed and single-use system for monocyte enrichment: potential for dendritic cell generation for clinical applications. Transfusion 42003;3:481–7.
   Google Scholar
• Sorg RV, Ozcan Z, Brefort T, Fischer J, Ackermann R, Muller M, Wernet P. Clinical-scale generation of dendritic cells in a closed system. J Immunother 2003;26:374–83.
   PubMed Web of Science ®Google Scholar
• Wong EC, Maher VE, Hines K, Lee J, Carter CS, Goletz T, . Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 2001;3:19–29.
   PubMed Web of Science ®Google Scholar
• Babatz J, Rollig C, Oelschlagel U, Zhao S, Ehninger G, Schmitz M, Bornhauser M. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. J Hematother Stem Cell Res 2003;12:515–23.
   PubMedGoogle Scholar
• Chen Y, Hoecker P, Zeng J, Dettke M. Combination of Cobe AutoPBSC and Gambro Elutra as a platform for monocyte enrichment in dendritic cell (DC) therapy: clinical study. J Clin Apher 2008;23:157–62.
   PubMed Web of Science ®Google Scholar
• Faradji A, Bohbot A, Schmitt-Goguel M, Dumont S, Eischen A, Wiesel ML, . Apheresis-elutriation program for adoptive immunotherapy with autologous activated monocytes in cancer patients. Int J Artif Organs 1991;14:304–12.
   Google Scholar
• Whiteside TL, Piazza P, Reiter A, Stanson J, Connolly NC, Rinaldo CR Jr, Riddler SA. Production of DC-based vaccine containing inactivated autologous virus for therapy of patients with chronic HIV-1 infection. Clin Vaccine Immunol 2009;16:233–40.
   PubMedGoogle Scholar
• Berger CL, Edelson RL. Comparison of lymphocyte function after isolation by ficoll-hypaque flotation or elutriation. J Invest Dermatol 1979;73:231–5.
   PubMed Web of Science ®Google Scholar
• Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef GC, . Generation of large numbers of dendritic cells in a closed system using Cell factories. J Immunol Methods 2002;264:135–51.
   PubMed Web of Science ®Google Scholar
• Chabannon C, Novakovitch G, Blache JL, Olivero S, Camerlo J, Genre D, . The role of autologous hematopoietic progenitor and cell reinfusion for intensive chemotherapy in women with poor-prognosis breast cancer. Clinical studies with ex-vivo expanded cells produced with the Aastrom Replicell technology. Hematol Cell Ther 1999;41:78–81.
   Google Scholar
• Jaroscak J, Goltry K, Smith A, Waters-Pick B, Martin PL, Driscoll TA, . Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell system. Blood 2003;101:5061–7.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res 2003;9:3562–70.
   PubMed Web of Science ®Google Scholar
• Motta MR, Castellani S, Rizzi S, Curti A, Gubinelli F, Fogli M, . Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol 2003;121:240–50.
   PubMedGoogle Scholar
• Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau DA, Vuk-Pavlovic S. Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy 2004;6:563–70.
   PubMed Web of Science ®Google Scholar
• Barfield RC, Otto M, Houston J, Holladay M, Geiger T, Martin J, . A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 2004;6:1–6.
   PubMed Web of Science ®Google Scholar
• Humeau L, Cohen R, Encinas T, Skripchenko Y, Lemiale F, Andre K, . Design and implementation of VRX496 phase II cell processing for cGMP production of multiple doses of lentivirally transduced autologous HIV infected CD4+ T lymphocytes. . 2006; :s427.
   Google Scholar
• Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I. Clinical grade Treg: GMP isolation, improvement of purity by CD127 depletion, Treg expansion, and Treg cryopreservation. PLoS ONE 2008;3:e3161.
   PubMedGoogle Scholar
• Powell DJ Jr, Parker LL, Rosenberg SA. Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples. J Immunother 2005;28:403–11.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Nakamura K, Kanayama K, Akiho H, Teshima T, Takayanagi R. Preparation of functionally preserved CD4+ CD25high regulatory T cells from leukapheresis products from ulcerative colitis patients, applicable to regulatory T-cell transfer therapy. Cytotherapy 2008;10:698–710.
   Web of Science ®Google Scholar
• Wichlan DG, Roddam PL, Eldridge P, Handgretinger R, Riberdy JM. Efficient and reproducible large-scale isolation of human CD4+ CD25+ regulatory T cells with potent suppressor activity. J Immunol Methods 2006;315:27–36.
   Google Scholar
• Bank I, Chess L. Perturbation of the T4 molecule transmits a negative signal to T cells. J Exp Med 1985;162:1294–303.
   PubMed Web of Science ®Google Scholar
• Bernard F, Jaleco S, Dardalhon V, Steinberg M, Yssel H, Noraz N, Taylor N, Kinet S. Ex vivo isolation protocols differentially affect the phenotype of human CD4+ T cells. J Immunol Methods 2002;271:99–106.
   PubMed Web of Science ®Google Scholar
• Desbarats J, Freed JH, Campbell PA, Newell MK. Fas (CD95) expression and death-mediating function are induced by CD4 cross-linking on CD4+ T cells. Proc Natl Acad Sci USA 1996;93:11014–8.
   PubMedGoogle Scholar
• Harding , S , Lipp P, Alexander DR. A therapeutic CD4 monoclonal antibody inhibits TCR-zeta chain phosphorylation, zeta-associated protein of 70-kDa Tyr319 phosphorylation, and TCR internalization in primary human T cells. J Immunol 2002;169:230–8.
   PubMedGoogle Scholar
• Haughn L, Gratton S, Caron L, Sekaly RP, Veillette A, Julius M. Association of tyrosine kinase p56lck with CD4 inhibits the induction of growth through the alpha beta T-cell receptor. Nature 1992;358:328–31.
   PubMedGoogle Scholar
• Jabado N, Pallier A, Le Deist DF, Bernard F, Fischer A, Hivroz C. CD4 ligands inhibit the formation of multifunctional transduction complexes involved in T cell activation. J Immunol 1997;158:94–103.
   PubMedGoogle Scholar
• Newell MK, Haughn LJ, Maroun CR, Julius MH. Death of mature T cells by separate ligation of CD4 and the T-cell receptor for antigen. Nature 1990;347:286–9.
   PubMed Web of Science ®Google Scholar
• Robinet E, Fournel S, Fatmi A, Revillard JP. IL-2-resistant hyporesponsiveness induced by CD4 mAbs in OKT3-activated human T cells is reversed by CD45RA triggering. Cell Immunol 1996;167:1–7.
   Google Scholar
• Woods M, Guy R, Waldmann H, Glennie M, Alexander DR. A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69. Cell Immunol 1998;185:101–13.
   Google Scholar
• Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 2006;176:7726–35.
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005;105:241–50.
   PubMed Web of Science ®Google Scholar
• Shen , X , Zhou J, Hathcock KS, Robbins P, Powell DJ Jr, Rosenberg SA, Hodes RJ. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 2007;30:123–9.
   PubMed Web of Science ®Google Scholar
• Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 2005;28:53–62.
   PubMed Web of Science ®Google Scholar
• Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005;175:7046–52.
   PubMed Web of Science ®Google Scholar
• Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, Thompson CB, June CH. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997;159:5921–30.
   PubMed Web of Science ®Google Scholar